| Bioactivity | Simlukafusp alfa (FAP-IL2v) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAPα) and an IL-2 variant that only binds IL-2Rβγ. Isotype: human IgG1[1]. |
| Invitro | Simlukafusp alfa (FAP-IL2v) 与 huIL-2Rβγ、cyIL-2Rβγ、muIL-2Rβγ、huFAP、cyFAP 和 muFAP的结合常数分别为 43±9 pM、80±20 pM、660±80 pM、0.3 nM、0.23 nM 和 0.5 nM[1]。Simlukafusp alfa (0-100 nM; 5 days) 在体外激活 CD4+/CD8+ T 细胞和 NK 细胞，但不优先激活 Tregs[1]。Simlukafusp alfa (0-100 nM) 体外增强 Cetuximab (HY-P9905) 介导的抗体依赖细胞毒性 (ADCC) 和 Cibisatamab (HY-P99011) 介导的 T 细胞依赖细胞毒性 (TDCC)[1]。 Cell Proliferation Assay[1] Cell Line: |
| In Vivo | Simlukafusp alfa (FAP-IL2v) (1 mg/kg; i.v.; weekly for 4 weeks) 在人类癌症小鼠模型中与治疗性抗体联合有效[1]。 Animal Model: |
| Name | Simlukafusp alfa |
| CAS | 1776942-10-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Waldhauer I, et al. Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy. MAbs. 2021 Jan-Dec;13(1):1913791. |